Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MediciNova, Inc.
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
June 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
June 05, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
June 03, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
May 28, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
May 14, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
May 07, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
April 02, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 26, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
March 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
March 12, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
January 17, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
December 21, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
December 06, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
November 19, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
October 27, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
October 10, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives Gene Therapy Milestone Payment
October 04, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
September 27, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
August 17, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
August 16, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
August 15, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
August 14, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
June 29, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
May 14, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
April 30, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
March 09, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
February 20, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
February 08, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
January 30, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Tickers
MNOV
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.